	US 11,918,587 B2
	Treatment of cancer with a RAF inhibitor
Aleksandra Franovic, Del Mar, CA (US); Eric Martin, Del Mar, CA (US); Nichol L. G. Miller, Poway, CA (US); Eric Murphy, San Marcos, CA (US); Richard Thomas Williams, Newbury Park, CA (US); and Ken Kobayashi, Rancho Santa Fe, CA (US)
Assigned to KINNATE BIOPHARMA INC., San Diego, CA (US)
Filed by Kinnate Biopharma Inc., San Diego, CA (US)
Filed on Apr. 6, 2023, as Appl. No. 18/296,726.
Application 18/296,726 is a continuation of application No. PCT/US2022/025875, filed on Apr. 22, 2022.
Claims priority of provisional application 63/178,922, filed on Apr. 23, 2021.
Prior Publication US 2023/0255977 A1, Aug. 17, 2023
Int. Cl. A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/5377 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01)]

20 Claims

1. A method of treating a cancer in a patient in need thereof, comprising administering to the patient (S)-N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)- 6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl) pyrrolidine-1-carboxamide, or pharmaceutically acceptable salt or solvate thereof, wherein the cancer is characterized as having an oncogenic BRAF alteration, and wherein the cancer is metastatic melanoma.